ClinicalTrials.gg
RecruitingNCT06888193BE CARINGUpdated Sep 18, 2026

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Phase 1 interventional study of Bimekizumab in Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis, sponsored by UCB Biopharma SRL. Recruiting at 14 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing bimekizumab in Arthritis, Psoriatic — 2 open to participants now, 3 under way, 1 of them phase 3. bimekizumab · Arthritis, Psoriatic.

Planned enrollment
13th of 14
20 · median 210
Started
2025
with 1 other
Phase 1
2 of 14
1 open now
Registered
13th of 14
by date
Lead sponsor
10 of 14
UCB Biopharma SRL

Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, this one is the 13th largest by planned enrollment, is one of 2 that started in 2025, is one of 2 in phase 1, and was the 13th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 14 studies testing bimekizumab in Arthritis, Psoriatic are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing bimekizumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.

03

Conditions studied

  • Moderate to Severe Plaque Psoriasis
  • Psoriatic Arthritis
  • Axial Spondyloarthritis
  • Hidradenitis Suppurativa

Keywords

  • Bimekizumab
  • Breastfeeding mothers
  • Bimzelx®
  • PSO
  • HS
  • AxSpa
  • PsA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be at least 18 years of age at the time of signing the .
  • Study participant is being treated with commercial bimekizumab per locally approved prescribing information and in accordance with her treating physician.
  • Study participant is breastfeeding and intends to breastfeed throughout the Sampling Period.
  • The decision to treat with bimekizumab and to breastfeed is made independently from and prior to the study participant consenting to participate in the study.
  • Study participant must be on bimekizumab treatment for at least 12 weeks after delivery and since starting/restarting/continuing bimekizumab prior to sampling (prior to start of the Sampling Period).
  • A female study participant is eligible to participate if she is not pregnant and does not plan to become pregnant during the study.

Exclusion criteria

Exclusion Criteria:

  • Study participant has any medical, obstetrical, or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study.
  • The infant has any abnormality noted on physical examination or medical history that, in the opinion of the Investigator, may jeopardize or compromise study participation.
  • Study participant has a history of chronic alcohol or drug abuse within the previous last year.
  • Study participant has history of breast implants, breast augmentation, or breast reduction surgery.
  • Study participant plans a surgical intervention during the Screening Period and Sampling Period or anticipates having surgery while participating in the Sampling Period (does not apply to tubal ligation).
  • Study participant or her infant has participated in another study of an medicinal product (IMP) (and/or an investigational device) within the previous 6 months or is currently participating in another study of an IMP (and/or an investigational device), unless the study is UCB PS0036 or a bimekizumab registry study.
  • Study participant or her infant has previously participated (ie, entered the sampling period) in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Bimekizumab

    Breastfeeding mothers who are already receiving commercial bimekizumab per locally approved prescribing information and in consultation and agreement with their treating physicians will participate in this study. Study participants will continue receiving commercially available bimekizumab under the care of their treating physician.

    Drug: Bimekizumab

Interventions

  • Bimekizumab under the care of their treating physician.

    Also known as: Bimzelx®

06

What researchers measure

Primary outcomes

  1. Concentration of bimekizumab in the breast milk on Day 1

    Breast milk samples will be collected predose on Day 1.

    Time frame: Day 1

  2. Concentration of bimekizumab in the breast milk on Day 2

    Breast milk samples will be collected predose on Day 2.

    Time frame: Day 2

  3. Concentration of bimekizumab in the breast milk on Day 3

    Breast milk samples will be collected predose on Day 3.

    Time frame: Day 3

  4. Concentration of bimekizumab in the breast milk on Day 5

    Breast milk samples will be collected predose on Day 5.

    Time frame: Day 5

  5. Concentration of bimekizumab in the breast milk on Day 7

    Breast milk samples will be collected predose on Day 7.

    Time frame: Day 7

  6. Concentration of bimekizumab in the breast milk on Day 9

    Breast milk samples will be collected predose on Day 9.

    Time frame: Day 9

  7. Concentration of bimekizumab in the breast milk on Day 11

    Breast milk samples will be collected predose on Day 11.

    Time frame: Day 11

  8. Concentration of bimekizumab in the breast milk on Day 13

    Breast milk samples will be collected predose on Day 13.

    Time frame: Day 13

  9. Concentration of bimekizumab in the breast milk on Day 15

    Breast milk samples will be collected predose on Day 15.

    Time frame: Day 15

  10. Concentration of bimekizumab in the breast milk on Day 29

    Breast milk samples will be collected predose on Day 29 for mothers on every 4 weeks (Q4W) dosing regimen.

    Time frame: Day 29

  11. Concentration of bimekizumab in the breast milk on Day 57

    Breast milk samples will be collected predose on Day 57 for mothers on every 8 weeks (Q8W) dosing regimen.

    Time frame: Day 57

Secondary outcomes

  1. Estimated Infant Dosage of bimekizumab from breast milk

    Breast milk samples will be collected predose on Day 1 (bimekizumab dosing day), Days 2, 3, 5, 7, 9, 11, 13, and 15 for all study participants (Day 15 predose if every 2 weeks (Q2W) dosing regimen), predose on Day 29 (if Q4W dosing regimen) or Day 57 (if Q8W dosing regimen).

    Time frame: Predose on Day 1, 2, 3, 5, 7, 9, 11, 13, 15, 29 and 57

  2. Relative Infant Dose of bimekizumab from breast milk

    Breast milk samples will be collected predose on Day 1 (bimekizumab dosing day), Days 2, 3, 5, 7, 9, 11, 13, and 15 for all study participants (Day 15 predose if every 2 weeks (Q2W) dosing regimen), predose on Day 29 (if Q4W dosing regimen) or Day 57 (if Q8W dosing regimen).

    Time frame: Predose on Day 1, 2, 3, 5, 7, 9, 11, 13, 15, 29 and 57

  3. Treatment-emergent Adverse Events (TEAEs) of the mother from time of informed consent through SFU contact

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.

    Time frame: From time of informed consent up to approximately 17 weeks

07

Study locations

14 of 14 sites recruiting
  • Up0122 105
    Santa Monica, California 90404, United States
    Recruiting
  • Up0122 103
    South Miami, Florida 33155, United States
    Recruiting
  • Up0122 104
    Boston, Massachusetts 02215, United States
    Recruiting
  • Up0122 106
    Chapel Hill, North Carolina 27516, United States
    Recruiting
  • Up0122 102
    Durham, North Carolina 27710, United States
    Recruiting
  • Up0122 101
    Milwaukee, Wisconsin 53226, United States
    Recruiting
  • Up0122 202
    Calgary, Canada
    Recruiting
  • Up0122 201
    Vancouver, Canada
    Recruiting
  • Up0122 301
    Freiburg im Breisgau, Germany
    Recruiting
  • Up0122 303
    Herne, Germany
    Recruiting
  • Up0122 501
    Barcelona, Spain
    Recruiting
  • Up0122 502
    Barcelona, Spain
    Recruiting
  • Up0122 602
    Lausanne, Switzerland
    Recruiting
  • Up0122 601
    Sankt Gallen, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Due to the small sample size in this trial, individual patient-level data cannot be adequately anonymized as there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 15 phase 1 interventional studies under Arthritis, Psoriatic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 35. This study's planned 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2025
First posted
Mar 21, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06888193
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Nov 5, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

UCB Cares
Contact
ucbcares@ucb.com
1-844-599-2273 (USA)
UCB Cares
Contact
ucbcares@ucb.com
001 844 599 2273 (USA)
UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion